Mario Rizzetto

Plain English
This study looked at how effective new immunotherapy drugs, called anti-PD-1 and PD-L1, are for treating advanced ovarian cancer. After reviewing data from ten clinical trials with nearly 7,847 patients, the researchers found that these drugs did not significantly improve the time patients lived without their cancer getting worse (progression-free survival) compared to standard treatments. This matters because ovarian cancer is difficult to treat, and finding effective therapies is crucial for improving patient outcomes. Who this helps: This research helps doctors and cancer researchers understand the limitations of current immunotherapy options for ovarian cancer patients.

Plain English
This study looked at patients in Italy who had both hepatitis D virus (HDV) and hepatitis B virus (HBV) and were on the liver transplant waiting list from 2011 to 2020. Among 1,731 patients, those with both infections had a better chance of surviving five years after transplant (83.2%) than those with only HBV (71.6%). This is important because it shows that patients with both viruses can have positive outcomes and might not need as complicated treatment plans after their transplants. Who this helps: This benefits patients with hepatitis D and B, as well as healthcare providers managing their care.

Plain English
This study looked at the expanded newborn screening program in the Lombardy region of Italy from 2016 to 2020, which tests newborns for rare metabolic disorders. Out of over 343,000 babies tested, 1,414 were flagged for further evaluation, with 209 ultimately diagnosed with these disorders. This screening helps identify and treat conditions early to prevent severe health problems later on. Who this helps: This benefits newborns and their families by enabling early detection and treatment of metabolic disorders.

Plain English
This research paper focuses on how to effectively screen, diagnose, and treat hepatitis D virus (HDV), which is a severe liver infection affecting millions worldwide. The panel of experts found that systematic screening for HDV in people who already have hepatitis B (HBsAg-positive) is crucial, and they recommend using a drug called bulevirtide for long-term treatment. Screening and effective treatment are important because they can prevent serious liver damage and improve patient outcomes. Who this helps: This benefits patients with hepatitis B and HDV, along with their healthcare providers.

Plain English
This study looked at a 72-year-old woman with advanced endometrial cancer, a type of cancer that’s becoming more deadly. After trying several treatments that did not work, she received a medication called trastuzumab deruxtecan (T-DXd), which led to a complete disappearance of the cancer as shown by imaging tests, and she remained free of disease symptoms for over eight months. This matters because it shows that T-DXd can effectively treat HER2-positive endometrial cancer even after other treatments have failed, highlighting the potential for new treatment options in challenging cases. Who this helps: Patients with HER2-positive endometrial cancer who have limited treatment options.

Plain English
This research examined a new type of organic fertilizer made from treated food waste, called activated granulated digestate, to see if it could work as well as traditional chemical fertilizers for growing tomatoes. The study found that tomatoes grown with this activated digestate yielded about 56 grams per plant, which is similar to the 62 grams per plant from chemical fertilizers, and even higher than regular untreated digestate by 21-30%. Additionally, this method increased the nutritional value of the tomatoes, specifically boosting the beneficial compound lycopene by up to 15.8%. Who this helps: This benefits farmers and consumers who want healthier crops and more sustainable farming practices.

Plain English
This study looked at the impact of the hepatitis D virus (HDV) on both native Italians and immigrants in Italy, examining 515 patients who were positive for hepatitis B. They found that 83.9% of these patients had detectable levels of the virus, with native Italians generally being older and more likely to suffer from severe liver conditions like cirrhosis (70.3% vs. 50.5% in migrants) and liver cancer (14.8% vs. 0.5% in migrants). The findings are important because they show that while severe liver disease is frequent in both groups, many patients actually have milder cases, which suggests that the treatment and care for chronic HDV infections may need to be tailored differently for these populations. Who this helps: This information benefits patients and doctors by providing insights for better management of hepatitis D infections.

Plain English
This study looked at how well the drug cemiplimab works for patients with advanced cervical cancer in Italy, outside of controlled clinical trials. Researchers found that patients lived for an average of 12 months after starting treatment, with some showing signs of improvement: about 8.6% had no evidence of disease and 21.1% had a partial response. The most common side effects were anemia, affecting nearly 39% of patients, and fatigue, impacting 27%. Who this helps: This research benefits patients with advanced cervical cancer and their doctors by providing real-world evidence about the effectiveness and safety of cemiplimab.

Plain English
This study looked at the long-term effects of hepatitis delta, a serious liver infection, in patients from various regions around the world, involving 648 participants from 14 centers in 11 countries. Researchers found that 32% of these patients experienced severe liver complications within an average of 3.5 years, with those from South Asia facing the highest risks and mortality rates. The findings highlight the urgent need for better access to treatments and education about managing hepatitis D, particularly for patients in regions with high disease severity. Who this helps: Patients suffering from hepatitis delta and healthcare providers treating them.

Plain English
This study looked at tiny molecules called micro-RNAs (miRNAs) in the blood of 20 patients with chronic hepatitis D who were being treated with a medication called pegylated interferon alpha. Researchers found that 40% of the patients (8 out of 20) responded positively to the treatment, and certain miRNAs, particularly miR-155-5p, were linked to treatment outcomes. Specifically, higher levels of miR-155-5p corresponded with lower levels of the virus, which suggests it could help predict how well patients might respond to this therapy. Who this helps: This helps patients with chronic hepatitis D and their doctors by providing a potential tool to monitor treatment effectiveness.

Plain English
The study looked at the economic impact of new guidelines for preventing Hepatitis B infection in patients who receive liver transplants. Researchers found that following these updated guidelines could save around €235.65 million after 5 years and about €540.73 million after 10 years by allowing for a quicker stop to certain treatments, depending on patients' risk levels. This is important because it shows how improved guidelines not only enhance patient care but also significantly reduce healthcare costs. Who this helps: This helps patients who receive liver transplants and healthcare decision-makers.

Plain English
This study looked at ways to help cancer patients manage nausea and vomiting caused by chemotherapy. It found that patients who received both oral information and an informative booklet had significantly less severe nausea (3.0% vs. 10.8%) and less impact on their daily lives (4.2% vs. 10.1%) compared to those who only received oral information. This is important because it shows that a simple educational program can improve the quality of life for cancer patients during treatment without needing a lot of resources. Who this helps: This helps cancer patients undergoing chemotherapy.

Plain English
This study examined the effects of a soy-based diet on adult zebrafish and found that after four weeks, the diet caused inflammation in the zebrafish's intestines. Specifically, there was a noticeable increase in harmful immune cells and certain inflammatory markers by the second week, which continued to escalate by the fourth week. Understanding this inflammation helps researchers learn more about how food can affect gut health, which is important for tackling inflammatory bowel diseases in humans. Who this helps: This helps patients with inflammatory bowel diseases and the doctors who treat them.

Plain English
This study looked at how to treat chronic viral hepatitis caused by different viruses, specifically Hepatitis B, C, and D. It found that new treatments for Hepatitis C can cure over 95% of patients, while treatment for Hepatitis D is more complicated but improves when combining newer drugs with existing ones. These advancements are important because they significantly improve patient outcomes and may help achieve global goals for eliminating hepatitic infections. Who this helps: This helps patients suffering from chronic viral hepatitis, particularly those with Hepatitis C and D.

Plain English
This study looks at liver transplantation for people infected with both hepatitis B and hepatitis D viruses, especially since hepatitis D is a severe liver disease that often leads to cirrhosis. It found that liver transplants, which started in 1987, have improved over time, and using a combination of antiviral treatments and immunoglobulins can help prevent reinfection in these patients. This matters because it highlights how we can make organ transplants more effective and accessible, particularly in countries where hepatitis D is more common. Who this helps: This helps patients with hepatitis B and D, especially those in need of a liver transplant.

Plain English
This study focused on a new testing method called droplet digital PCR (ddPCR) to measure the amount of Hepatitis Delta virus (HDV) in patients’ blood. The researchers found that ddPCR provided precise results that were almost identical to the traditional testing methods, with a strong agreement rate of 95%. This is important because it offers a reliable way to measure HDV, which can help doctors better manage and treat patients with this infection. Who this helps: This benefits patients with Hepatitis Delta virus and their doctors.

Plain English
This study looked at the quality of different tests used to diagnose SARS-CoV-2 (the virus that causes COVID-19) in Lombardy, Italy, from 2020 to 2022. They found that a high percentage of tests were accurate: 97.7% for molecular tests, 93.9% for antibody tests, and 85% for antigen tests. This research is important because it shows that the testing methods used in this region are generally reliable, which helps ensure that people get the right diagnoses and treatments for COVID-19. Who this helps: Patients and healthcare providers in Lombardy.

Plain English
This study looked at hepatitis D, a virus that needs the hepatitis B virus to infect people. It is the smallest virus that infects humans and causes serious liver problems. While vaccines for hepatitis B have helped reduce hepatitis D in developed countries, it is still a major health issue in many developing regions. Who this helps: This information benefits patients with liver disease, particularly those in developing countries.

Plain English
This research paper looks at Hepatitis D, a serious liver infection that depends on Hepatitis B for it to occur. The study highlights that Hepatitis D is controlled well in wealthy countries due to vaccination against Hepatitis B, but it remains a significant issue in poorer countries. Testing for Hepatitis D in people already infected with Hepatitis B is crucial, and while the current treatment isn't very effective, new treatments are in development. Who this helps: This helps patients with Hepatitis B and Hepatitis D, particularly in developing countries.

Plain English
This study looked at how common hepatitis D virus infection is in Africa and Asia, highlighting that the rates of infection vary a lot across different regions and studies. Researchers found that these differences often come from how patients were chosen for testing, which can lead to misleading results. Understanding the true prevalence of hepatitis D is important for developing better treatment strategies and improving patient care. Who this helps: This benefits patients with hepatitis D and the doctors treating them.

Plain English
This study looked at how the spread of hepatitis D (HDV) is changing. It found that in wealthy countries, there are now two main groups affected: older adults who have severe liver damage and younger immigrants who are getting infected. In places where hepatitis D is common, people often get serious liver diseases like cirrhosis much faster. Despite some advancements in treatment, most patients still cannot be cured. Who this helps: This research is important for doctors treating patients with hepatitis D and for healthcare planning in communities at risk.

Plain English
This paper reviews the progress made in understanding Hepatitis D, a virus that can cause serious liver damage in patients who are also infected with Hepatitis B. Over the past 45 years, researchers have worked on treatments and prevention methods, finding that about 5% of people with Hepatitis B also have Hepatitis D. Understanding these connections is crucial because it can lead to better care and management for affected patients. Who this helps: Patients with Hepatitis B and Hepatitis D.

Plain English
This study focused on how to prevent the return of hepatitis B virus (HBV) infection in patients who receive liver transplants. The researchers reviewed existing practices and created 50 recommendations based on their findings, which include using a combination of treatments for different risk levels of HBV patients. For low-risk patients, they suggest a short-term treatment for four weeks, while high-risk patients may need a year of combined therapy to avoid complications. Who this helps: This information benefits patients undergoing liver transplantation, especially those with hepatitis B, as well as their doctors in managing their care.

Plain English
This study focused on hepatitis D virus (HDV) infections in Italy, specifically examining 121 Italian patients with chronic HDV liver disease over nearly a decade. It found that by the end of the monitoring period, 71.1% of these patients had cirrhosis, and 66.1% still had active HDV infections. Despite HDV infections decreasing in the general population, the ongoing health issues in older Italian patients are significant for liver transplant programs. Who this helps: This information benefits doctors and healthcare providers managing liver health in older patients.

Plain English
This study looked at the problems caused by the hepatitis B virus (HBV) when patients receiving immune-suppressing treatments reactivate the virus. Researchers found that the risk of reactivation is higher in patients who test positive for the virus but is lower for those who don’t have the surface antigen. In this case, a patient with leukemia and a kidney transplant experienced reactivation, which suggests that measuring a certain hepatitis B marker could help in managing patients who might be at risk due to genetic changes in the virus. Who this helps: This helps patients with hepatitis B who are undergoing treatments that weaken their immune systems.

Plain English
This study focused on how an enzyme called Glutamine Synthetase 1 (GS1) affects nerve cells in the context of Huntington's disease. Researchers found that by increasing GS1 levels in neurons, they could reduce the harmful protein aggregates associated with the disease and improve movement problems in a lab model by promoting a process called autophagy, which clears out damaged proteins. This is important because it suggests a potential new way to help protect neurons and improve health in conditions like Huntington's disease. Who this helps: Patients with Huntington's disease and their families.

Plain English
This study looked at a new test for measuring a specific antibody related to hepatitis B (HBV) in the blood of people with active and hidden infections. Researchers found that the test performed very well, with an accuracy of 98.7%, and showed that antibody levels changed based on the infection stage, declining during treatment. This is important because it can help doctors better understand and manage hepatitis B infections, improving patient care. Who this helps: This helps patients with hepatitis B and their doctors.

Plain English
The study focused on improving treatment for chronic hepatitis D (CHD), which currently relies on an outdated therapy called interferon alpha with limited success. Researchers reviewed new potential treatments and found that a combination of a drug called REP 2139 with interferon led to the disappearance of the virus in about half of the patients tested, while two other drugs, Myrcludex B and Lonafarnib, showed promise when combined with interferon as well. This research is crucial because it may lead to more effective treatments for a condition that currently lacks good options. Who this helps: This benefits patients suffering from chronic hepatitis D.

Plain English
This study investigated whether adding peginterferon alfa-2a to standard nucleos(t)ide analogue therapy could improve treatment results for Caucasian patients with a specific type of chronic hepatitis B virus infection (genotype D) who are negative for the hepatitis B e antigen. Researchers found that 67.4% of the patients showed at least a 50% decrease in a key virus marker (HBsAg) after 48 weeks of combined treatment, which is a significant improvement in managing this condition. This matters because reducing HBsAg levels can help lower the risk of liver damage and improve overall health for these patients. Who this helps: Patients with hepatitis B who are negative for the e antigen and have genotype D.

Plain English
This study examined the effectiveness of a 24-week treatment using a combination of drugs (ombitasvir, paritaprevir, and ribavirin) for patients with hepatitis C genotype 4 who also had compensated cirrhosis. The results showed that 93.4% of patients who had never been treated before successfully cleared the virus after 12 weeks, and all patients who had been treated previously also cleared the virus. The findings suggest that extending treatment beyond 12 weeks does not provide any additional benefits for these patients. Who this helps: This helps patients with hepatitis C genotype 4 and compensated cirrhosis.

Plain English
This study looked at treating chronic hepatitis delta, a severe type of viral hepatitis, and found that existing treatments, mainly interferons, aren’t very effective. It highlights the need for better ways to measure how well new treatments are working, proposing specific goals that researchers can use in clinical trials to improve future treatment developments. This is important because finding effective treatments and clearly measuring their success can lead to better health outcomes for patients. Who this helps: Patients with chronic hepatitis delta.

Plain English
This study looked at how being overweight or having other metabolic conditions affects the health of patients with chronic hepatitis C who successfully treated the virus. Out of 1,034 patients treated, about 37% cleared the virus, and researchers found that those with fatty liver were more likely to experience heart disease or develop type 2 diabetes over an 11-year follow-up period compared to those without fatty liver. Specifically, the chances of these serious health issues were significantly higher for those with fatty liver—5 times more likely for heart problems and 2.6 times more likely for diabetes. Who this helps: This information helps doctors and patients by highlighting the importance of managing weight and metabolic health after treating hepatitis C.

Plain English
This study examined the connection between certain genetic markers, gut health, and the effects of a gluten-free and casein-free diet in children with autism spectrum disorders (ASD) who also have gastrointestinal (GI) issues. Out of 151 children studied, 72 (48%) had specific genetic markers, and 56 (37%) showed inflammation in the gut lining. Those with gut inflammation tended to improve on the diet, regardless of whether they strictly followed it, and the findings suggest that gut health plays a key role in the response to dietary changes, rather than just genetic factors. Who this helps: This helps children with autism and GI symptoms, as well as their parents and healthcare providers.

Plain English
This study looked at the impact of hepatitis D virus (HDV) infection in patients with chronic liver disease in Uzbekistan, where hepatitis B virus (HBV) is common. Researchers found that in the last three years, more than 80% of patients with cirrhosis caused by HBV also had HDV, with its prevalence increasing from 41% to 49.1%. This is significant because HDV is rapidly becoming a leading cause of severe liver problems in younger patients, with an average age of just 39 for those affected. Who this helps: This information benefits doctors and healthcare providers involved in treating patients with liver diseases in Uzbekistan.

Plain English
This study looked at how treating hepatitis C (HCV) with new antiviral medications affects blood sugar levels in patients who also have type 2 diabetes. Out of 110 treated patients, those who successfully cleared the virus saw their average fasting blood sugar drop from 152 to 134 mg/dL and their hemoglobin A1c levels (a measure of long-term blood sugar control) decrease from 52 to 46.5 mmol/mol. This is important because it shows that clearing HCV can lead to better blood sugar management, allowing one in five patients to lower or stop their diabetes medications. Who this helps: This benefits diabetic patients who also have hepatitis C.

Plain English
This study looked at the effects of hepatitis D (HDV) infection on 1,576 patients from various regions of the world. It found that nearly half of the patients had cirrhosis, about 30 developed liver cancer, and many had different experiences based on where they lived. The results show that hepatitis D can vary greatly by region and emphasize the need for better treatment options. Who this helps: This helps patients with hepatitis D and healthcare providers working to manage their care.

Plain English
This study focused on new treatment methods for chronic hepatitis D, which depends on the hepatitis B virus for its life cycle. Researchers found that using a combination of the drug REP-2139 and pegylated interferon alpha led to lasting improvements in 5 out of 12 patients, successfully eliminating both hepatitis D and B virus markers. These findings are significant because they offer a potential new approach to treating a previously difficult-to-manage viral infection. Who this helps: This aids patients with chronic hepatitis D looking for more effective treatment options.

Plain English
This research looked at hepatitis C virus (HCV) infections in five big cities in Italy to better understand how common the virus is and who is most at risk. The study found that only 2.3% of nearly 5,000 people tested positive for HCV, with the infection being more common in older individuals—rising from 0.2% in younger people to 7.0% in those over 70. Almost 80% of those who tested positive were aware they had the virus, suggesting that the current measures for screening may not be necessary due to the declining number of new infections. Who this helps: This research benefits doctors and public health officials by guiding screening policies and treatment approaches for older patients.

Plain English
This study looked at the hidden presence of the hepatitis B virus (HBV) in the livers of 100 organ donors who tested positive for anti-HBc, which is an antibody indicating past HBV infection. The researchers found that 52% of these donors actually had what’s called occult HBV infection (OBI), and among those with OBI, 52% had detectable levels of a specific viral DNA form (cccDNA) in their livers, averaging about 13 copies per 10 cells. This is important because the findings suggest that measuring the level of anti-HBc antibodies can help identify patients at risk of HBV reactivation, particularly those undergoing treatments that weaken their immune system. Who this helps: Patients at risk of HBV reactivation, especially those receiving immunosuppressive therapies.

Plain English
This study looked at how certain parts of the hepatitis delta virus (HDV) might allow the virus to escape detection by the immune system, specifically focusing on T cells in patients. Researchers found two key immune response areas (or epitopes) that could be recognized in patients who cleared the virus, but in those with chronic infections, the virus had mutations that helped it avoid recognition by these T cells. This is important because understanding how HDV can escape the immune system can help improve treatment and vaccine strategies for the 20 million people affected by chronic hepatitis delta worldwide. Who this helps: Patients with chronic hepatitis delta virus infections.

Plain English
This study looked at ways to identify the risk of liver cancer in patients with cirrhosis caused by hepatitis B virus (HBV). Researchers tested three biomarkers—miR-122, AFP, and PIVKA-II—and found that using them together helped significantly improve the ability to predict cancer risk. Specifically, the combination showed an impressive ability to distinguish between cirrhosis and cancer, with a score of 0.918, and identified patients who were more than ten times more likely to develop liver cancer. Who this helps: This benefits patients with HBV-related cirrhosis and their doctors by allowing earlier cancer detection and improved monitoring.

Plain English
This study looks at new treatments for chronic hepatitis D, a liver infection that currently mainly relies on Interferon. Researchers are testing drugs that work in different ways, such as blocking the virus's ability to multiply and spread, with early results showing that one drug, REP 2139, reduced both HDV and a related protein in blood samples. Finding better treatments is important because hepatitis D can lead to severe liver damage, and these new drugs could work alongside existing treatments for better results. Who this helps: This research benefits patients with chronic hepatitis D who need better treatment options.